“a favorable trend”

Combined immunotherapy and antiangiogenic therapy also showed a favorable trend compared to Sunitinib regarding objective response rate (OR=2.53 (2.23, 2.87), P < 0.00001) (Figure 4 ).

With a few exceptions (ACE inhibitors, antidiabetics, and statins), no pharmacological treatment showed a favorable trend (i.e., higher frequency in survivors); whereas, patients treated with aldosterone antagonists were significantly more frequent ( p < 0.001) in non-survivors (30.0% vs. 13.8%).

Patients with pathologic complete response (ypT0N0) showed a favorable trend of OS and significantly longer RFS ( p = 0.0019) ( Figure 4 a,b).

Most subgroups benefited from nivolumab plus chemotherapy compared with chemotherapy alone, and the interim analysis showed a favorable trend for OS (HR = 0.57; p = 0.0079).

In addition, a favorable trend was found for diastolic blood pressure with CAD in the intervention group (time and group interaction, p = 0.017).

A favorable trend for better response was found for a higher IMRT-SIB dose ≥ 55 Gy (OR 0.57; 0.32–1.01, p = 0.056).

In other comparisons, statistical significance was not achieved, though a favorable trend was noted for combination therapy in clinical remission outcomes ( p = 0.0578 vs. golimumab; p = 0.041 vs. guselkumab).

A favorable trend was noted regarding mortality at 1 year for consultant-led operations vs nonconsultant-led operations (22.1% vs 27.9%, respectively; P =0.058).

This group showed a favorable trend to a higher mean age, but this difference was not statistically significant (p = 0.06).

AUC for CLEOS (0.72, 95% CI 0.62–0.81) was statistically superior to PRE (AUC 0.61, 95% CI 0.51–0.71; p = 0.0197), THRIVE (AUC 0.58, 95% CI 0.47–0.69; p<0.001), and SPAN-100 (AUC 0.54, 95% CI 0.48–0.60; p<0.001), and a favorable trend was observed compared to HIAT-2 (AUC 0.63, 95% CI 0.53–0.73; p = 0.0616) for predicting 90-day mRS 4–6 ( Fig 2 ).

Also, Kaplan–Meier curves for time to treatment failure (i.e., time to first emetic event or use of rescue medication) showed a separation after 96 h, with a favorable trend in the fosnetupitant group (hazard ratio 0.789; 95% CI 0.610, 1.021; P = 0.071).

In the ITT population, Cerebrolysin set a favorable trend to lower any HT with a rate of 15.9% versus 23.3% in the control group and a corresponding OR of 0.543 (95% CI: 0.281–1.05; p = 0.078).

In comparison to placebo, pioglitazone was linked with a favorable trend for macrovascular endpoints (19.7% vs. 21.7%; HR = 0.90, 95%CI 0.80-1.02, P = 0.095) [ 13 ].

A favorable trend in rwPFS was reported in patients receiving T-DXd as I/II line versus further lines (17 vs. 15 months; P = .098).

The UA showed better IPFS rates significantly related to male sex ( p = 0.049), a BED 12 of ≥42 Gy ( p = 0.006), and controlled extracranial disease ( p = 0.03); in the MA, a favorable trend towards LC ( p = 0.11) and higher BED ( p = 0.11) schedules maintained a correlation with improved IPFS rates, although statistical significance was not reached.

The analysis of secondary endpoints for MACEs also did not reach statistical significance, despite a favorable trend for the DK culotte (13% vs. 19%; p = 0.12).

A favorable trend was also observed for ORR (52.5% vs. 35.1%, p = 0.12) and OS (20.0 vs. 8.8 months; HR: 0.62; 95% CI: 0.35–1.10; p = 0.10) ( Figure 3 B).

There were no associations of VF with any ADRB2 variant, whereas the ADRA2C 322–325 Ins/Del genotype had a favorable OR (0.39 [0.22, 0.72], P =0.002) and Del carriers exhibited a favorable trend (OR 0.69, P =0.13).

Subclassifying AEs according to enteral stent patency, no significant difference was observed in terms of stent dysfunction rate (stent migration, stent obstruction, and relapse of GOO symptoms) between the two groups although a favorable trend was observed for EUS-GE (0% vs. 11.5 %, p = 0.16).

The proportion of patients surviving at the 12-month mark exhibited a favorable trend in the study group compared to the control (91.1% vs 87.6%), though statistical significance was not attained (p=0.202).

In contrast, the KEYNOTE-122 trial, which investigated pembrolizumab asmonotherapy in patients with recurrent or metastatic NPC who had previously failed platinum-based chemotherapy, did not report a significant improvement in OS in the pembrolizumab arm, despite showing a favorable trend (HR 0.9, 95% CI: 0.67–1.19, p = 0.2262).

Bcl-2 status was significant in ER-negative patients ( p = 0.010) and showed a favorable trend in ER-positive patients ( p = 0.259) (Fig. 3 ).

Comparing to treating only part of metastatic lesions, total irradiation of metastatic lesions was associated with superior PFS (HR, 0.44; 95 % CI, 0.18–1.11; p = 0.083), and higher radiation doses (BED 10 ≥ 60 Gy) showed a favorable trend to improve the PFS (HR, 0.71; 95 % CI, 0.36–1.39; p = 0.319).

The interim OS data did not suggest a favorable trend for osimertinib over placebo (36‐month OS rate, 84% vs. 74%, HR = 0.81, P = 0.53), indicating that the long‐term efficacy of LAURA treatment remains unclear.

Although there was a favorable trend, the study failed its primary composite endpoint (HR: 0.90; 95% CI: 0.78, p = 1.02).